 | • レポートコード：QY2207C3545 • 出版社/出版日：QYResearch / 2022年7月11日 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療機器 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Multi User | ￥1,087,800 (USD7,350) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症のパンデミックにより、世界の末期腎疾患（ESRD）療法の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に末期腎疾患（ESRD）療法の世界市場のxxx％を占める「血液透析」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「病院」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 中国の末期腎疾患（ESRD）療法の市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの末期腎疾患（ESRD）療法市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの末期腎疾患（ESRD）療法市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 末期腎疾患（ESRD）療法のグローバル主要メーカーには、Fresenius、DaVita、Baxter、Nipro、B. Braun、Asahi Kasei、Nikkiso、WEGO、Newsol、Mayo Clinic、Guangdong Biolight、Medtronic、Sanxin Medtec、Jafron Biomedical、SWS Hemodialysis Care、Tianyi Medicalなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 末期腎疾患（ESRD）療法市場は、種類と用途によって区分されます。世界の末期腎疾患（ESRD）療法市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。 【種類別セグメント】 血液透析、腹膜透析、腎臓移植 【用途別セグメント】 病院、腎臓透析センター、家庭、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 末期腎疾患（ESRD）療法製品概要 - 種類別市場（血液透析、腹膜透析、腎臓移植） - 用途別市場（病院、腎臓透析センター、家庭、その他） - 調査の目的 ・エグゼクティブサマリー - 世界の末期腎疾患（ESRD）療法販売量予測2017-2028 - 世界の末期腎疾患（ESRD）療法売上予測2017-2028 - 末期腎疾患（ESRD）療法の地域別販売量 - 末期腎疾患（ESRD）療法の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別末期腎疾患（ESRD）療法販売量 - 主要メーカー別末期腎疾患（ESRD）療法売上 - 主要メーカー別末期腎疾患（ESRD）療法価格 - 競争状況の分析 - 企業M&A動向 ・種類別市場規模（血液透析、腹膜透析、腎臓移植） - 末期腎疾患（ESRD）療法の種類別販売量 - 末期腎疾患（ESRD）療法の種類別売上 - 末期腎疾患（ESRD）療法の種類別価格 ・用途別市場規模（病院、腎臓透析センター、家庭、その他） - 末期腎疾患（ESRD）療法の用途別販売量 - 末期腎疾患（ESRD）療法の用途別売上 - 末期腎疾患（ESRD）療法の用途別価格 ・北米市場 - 北米の末期腎疾患（ESRD）療法市場規模（種類別、用途別） - 主要国別の末期腎疾患（ESRD）療法市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの末期腎疾患（ESRD）療法市場規模（種類別、用途別） - 主要国別の末期腎疾患（ESRD）療法市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の末期腎疾患（ESRD）療法市場規模（種類別、用途別） - 主要国別の末期腎疾患（ESRD）療法市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の末期腎疾患（ESRD）療法市場規模（種類別、用途別） - 主要国別の末期腎疾患（ESRD）療法市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの末期腎疾患（ESRD）療法市場規模（種類別、用途別） - 主要国別の末期腎疾患（ESRD）療法市場規模（トルコ、サウジアラビア） ・企業情報 Fresenius、DaVita、Baxter、Nipro、B. Braun、Asahi Kasei、Nikkiso、WEGO、Newsol、Mayo Clinic、Guangdong Biolight、Medtronic、Sanxin Medtec、Jafron Biomedical、SWS Hemodialysis Care、Tianyi Medical ・産業チェーン及び販売チャネル分析 - 末期腎疾患（ESRD）療法の産業チェーン分析 - 末期腎疾患（ESRD）療法の原材料 - 末期腎疾患（ESRD）療法の生産プロセス - 末期腎疾患（ESRD）療法の販売及びマーケティング - 末期腎疾患（ESRD）療法の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 末期腎疾患（ESRD）療法の産業動向 - 末期腎疾患（ESRD）療法のマーケットドライバー - 末期腎疾患（ESRD）療法の課題 - 末期腎疾患（ESRD）療法の阻害要因 ・主な調査結果 |
End-stage renal failure, also known as end-stage renal disease (ESRD), is can be caused by an underlying health problem, often diabetes or high blood pressure. ESRD is the final, permanent stage of chronic kidney disease, where kidney function has declined to the point that the kidneys can no longer function on their own. When the kidneys can no longer filter the blood of waste and extra fluid, patients need dialysis or a kidney transplant to survive.
Market Analysis and Insights: Global End Stage Renal Disease (ESRD) Therapy Market
The global End Stage Renal Disease (ESRD) Therapy market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Hemodialysis accounting for % of the End Stage Renal Disease (ESRD) Therapy global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospitals segment is altered to an % CAGR throughout this forecast period.
China End Stage Renal Disease (ESRD) Therapy market size is valued at US$ million in 2021, while the North America and Europe End Stage Renal Disease (ESRD) Therapy are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe End Stage Renal Disease (ESRD) Therapy landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global End Stage Renal Disease (ESRD) Therapy market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global End Stage Renal Disease (ESRD) Therapy market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global End Stage Renal Disease (ESRD) Therapy market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global End Stage Renal Disease (ESRD) Therapy market.
Global End Stage Renal Disease (ESRD) Therapy Scope and Market Size
End Stage Renal Disease (ESRD) Therapy market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global End Stage Renal Disease (ESRD) Therapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Hemodialysis
Peritoneal Dialysis
Kidney Transplantation
Segment by Application
Hospitals
Kidney Dialysis Centers
At Homes
Others
By Company
Fresenius
DaVita
Baxter
Nipro
B. Braun
Asahi Kasei
Nikkiso
WEGO
Newsol
Mayo Clinic
Guangdong Biolight
Medtronic
Sanxin Medtec
Jafron Biomedical
SWS Hemodialysis Care
Tianyi Medical
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global End Stage Renal Disease (ESRD) Therapy Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Hemodialysis
1.2.3 Peritoneal Dialysis
1.2.4 Kidney Transplantation
1.3 Market by Application
1.3.1 Global End Stage Renal Disease (ESRD) Therapy Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Kidney Dialysis Centers
1.3.4 At Homes
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global End Stage Renal Disease (ESRD) Therapy Market Perspective (2017-2028)
2.2 End Stage Renal Disease (ESRD) Therapy Growth Trends by Region
2.2.1 End Stage Renal Disease (ESRD) Therapy Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 End Stage Renal Disease (ESRD) Therapy Historic Market Size by Region (2017-2022)
2.2.3 End Stage Renal Disease (ESRD) Therapy Forecasted Market Size by Region (2023-2028)
2.3 End Stage Renal Disease (ESRD) Therapy Market Dynamics
2.3.1 End Stage Renal Disease (ESRD) Therapy Industry Trends
2.3.2 End Stage Renal Disease (ESRD) Therapy Market Drivers
2.3.3 End Stage Renal Disease (ESRD) Therapy Market Challenges
2.3.4 End Stage Renal Disease (ESRD) Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top End Stage Renal Disease (ESRD) Therapy Players by Revenue
3.1.1 Global Top End Stage Renal Disease (ESRD) Therapy Players by Revenue (2017-2022)
3.1.2 Global End Stage Renal Disease (ESRD) Therapy Revenue Market Share by Players (2017-2022)
3.2 Global End Stage Renal Disease (ESRD) Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by End Stage Renal Disease (ESRD) Therapy Revenue
3.4 Global End Stage Renal Disease (ESRD) Therapy Market Concentration Ratio
3.4.1 Global End Stage Renal Disease (ESRD) Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by End Stage Renal Disease (ESRD) Therapy Revenue in 2021
3.5 End Stage Renal Disease (ESRD) Therapy Key Players Head office and Area Served
3.6 Key Players End Stage Renal Disease (ESRD) Therapy Product Solution and Service
3.7 Date of Enter into End Stage Renal Disease (ESRD) Therapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 End Stage Renal Disease (ESRD) Therapy Breakdown Data by Type
4.1 Global End Stage Renal Disease (ESRD) Therapy Historic Market Size by Type (2017-2022)
4.2 Global End Stage Renal Disease (ESRD) Therapy Forecasted Market Size by Type (2023-2028)
5 End Stage Renal Disease (ESRD) Therapy Breakdown Data by Application
5.1 Global End Stage Renal Disease (ESRD) Therapy Historic Market Size by Application (2017-2022)
5.2 Global End Stage Renal Disease (ESRD) Therapy Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America End Stage Renal Disease (ESRD) Therapy Market Size (2017-2028)
6.2 North America End Stage Renal Disease (ESRD) Therapy Market Size by Type
6.2.1 North America End Stage Renal Disease (ESRD) Therapy Market Size by Type (2017-2022)
6.2.2 North America End Stage Renal Disease (ESRD) Therapy Market Size by Type (2023-2028)
6.2.3 North America End Stage Renal Disease (ESRD) Therapy Market Share by Type (2017-2028)
6.3 North America End Stage Renal Disease (ESRD) Therapy Market Size by Application
6.3.1 North America End Stage Renal Disease (ESRD) Therapy Market Size by Application (2017-2022)
6.3.2 North America End Stage Renal Disease (ESRD) Therapy Market Size by Application (2023-2028)
6.3.3 North America End Stage Renal Disease (ESRD) Therapy Market Share by Application (2017-2028)
6.4 North America End Stage Renal Disease (ESRD) Therapy Market Size by Country
6.4.1 North America End Stage Renal Disease (ESRD) Therapy Market Size by Country (2017-2022)
6.4.2 North America End Stage Renal Disease (ESRD) Therapy Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe End Stage Renal Disease (ESRD) Therapy Market Size (2017-2028)
7.2 Europe End Stage Renal Disease (ESRD) Therapy Market Size by Type
7.2.1 Europe End Stage Renal Disease (ESRD) Therapy Market Size by Type (2017-2022)
7.2.2 Europe End Stage Renal Disease (ESRD) Therapy Market Size by Type (2023-2028)
7.2.3 Europe End Stage Renal Disease (ESRD) Therapy Market Share by Type (2017-2028)
7.3 Europe End Stage Renal Disease (ESRD) Therapy Market Size by Application
7.3.1 Europe End Stage Renal Disease (ESRD) Therapy Market Size by Application (2017-2022)
7.3.2 Europe End Stage Renal Disease (ESRD) Therapy Market Size by Application (2023-2028)
7.3.3 Europe End Stage Renal Disease (ESRD) Therapy Market Share by Application (2017-2028)
7.4 Europe End Stage Renal Disease (ESRD) Therapy Market Size by Country
7.4.1 Europe End Stage Renal Disease (ESRD) Therapy Market Size by Country (2017-2022)
7.4.2 Europe End Stage Renal Disease (ESRD) Therapy Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific End Stage Renal Disease (ESRD) Therapy Market Size (2017-2028)
8.2 Asia-Pacific End Stage Renal Disease (ESRD) Therapy Market Size by Type
8.2.1 Asia-Pacific End Stage Renal Disease (ESRD) Therapy Market Size by Type (2017-2022)
8.2.2 Asia-Pacific End Stage Renal Disease (ESRD) Therapy Market Size by Type (2023-2028)
8.2.3 Asia-Pacific End Stage Renal Disease (ESRD) Therapy Market Share by Type (2017-2028)
8.3 Asia-Pacific End Stage Renal Disease (ESRD) Therapy Market Size by Application
8.3.1 Asia-Pacific End Stage Renal Disease (ESRD) Therapy Market Size by Application (2017-2022)
8.3.2 Asia-Pacific End Stage Renal Disease (ESRD) Therapy Market Size by Application (2023-2028)
8.3.3 Asia-Pacific End Stage Renal Disease (ESRD) Therapy Market Share by Application (2017-2028)
8.4 Asia-Pacific End Stage Renal Disease (ESRD) Therapy Market Size by Region
8.4.1 Asia-Pacific End Stage Renal Disease (ESRD) Therapy Market Size by Region (2017-2022)
8.4.2 Asia-Pacific End Stage Renal Disease (ESRD) Therapy Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America End Stage Renal Disease (ESRD) Therapy Market Size (2017-2028)
9.2 Latin America End Stage Renal Disease (ESRD) Therapy Market Size by Type
9.2.1 Latin America End Stage Renal Disease (ESRD) Therapy Market Size by Type (2017-2022)
9.2.2 Latin America End Stage Renal Disease (ESRD) Therapy Market Size by Type (2023-2028)
9.2.3 Latin America End Stage Renal Disease (ESRD) Therapy Market Share by Type (2017-2028)
9.3 Latin America End Stage Renal Disease (ESRD) Therapy Market Size by Application
9.3.1 Latin America End Stage Renal Disease (ESRD) Therapy Market Size by Application (2017-2022)
9.3.2 Latin America End Stage Renal Disease (ESRD) Therapy Market Size by Application (2023-2028)
9.3.3 Latin America End Stage Renal Disease (ESRD) Therapy Market Share by Application (2017-2028)
9.4 Latin America End Stage Renal Disease (ESRD) Therapy Market Size by Country
9.4.1 Latin America End Stage Renal Disease (ESRD) Therapy Market Size by Country (2017-2022)
9.4.2 Latin America End Stage Renal Disease (ESRD) Therapy Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa End Stage Renal Disease (ESRD) Therapy Market Size (2017-2028)
10.2 Middle East & Africa End Stage Renal Disease (ESRD) Therapy Market Size by Type
10.2.1 Middle East & Africa End Stage Renal Disease (ESRD) Therapy Market Size by Type (2017-2022)
10.2.2 Middle East & Africa End Stage Renal Disease (ESRD) Therapy Market Size by Type (2023-2028)
10.2.3 Middle East & Africa End Stage Renal Disease (ESRD) Therapy Market Share by Type (2017-2028)
10.3 Middle East & Africa End Stage Renal Disease (ESRD) Therapy Market Size by Application
10.3.1 Middle East & Africa End Stage Renal Disease (ESRD) Therapy Market Size by Application (2017-2022)
10.3.2 Middle East & Africa End Stage Renal Disease (ESRD) Therapy Market Size by Application (2023-2028)
10.3.3 Middle East & Africa End Stage Renal Disease (ESRD) Therapy Market Share by Application (2017-2028)
10.4 Middle East & Africa End Stage Renal Disease (ESRD) Therapy Market Size by Country
10.4.1 Middle East & Africa End Stage Renal Disease (ESRD) Therapy Market Size by Country (2017-2022)
10.4.2 Middle East & Africa End Stage Renal Disease (ESRD) Therapy Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Fresenius
11.1.1 Fresenius Company Details
11.1.2 Fresenius Business Overview
11.1.3 Fresenius End Stage Renal Disease (ESRD) Therapy Introduction
11.1.4 Fresenius Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022)
11.1.5 Fresenius Recent Developments
11.2 DaVita
11.2.1 DaVita Company Details
11.2.2 DaVita Business Overview
11.2.3 DaVita End Stage Renal Disease (ESRD) Therapy Introduction
11.2.4 DaVita Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022)
11.2.5 DaVita Recent Developments
11.3 Baxter
11.3.1 Baxter Company Details
11.3.2 Baxter Business Overview
11.3.3 Baxter End Stage Renal Disease (ESRD) Therapy Introduction
11.3.4 Baxter Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022)
11.3.5 Baxter Recent Developments
11.4 Nipro
11.4.1 Nipro Company Details
11.4.2 Nipro Business Overview
11.4.3 Nipro End Stage Renal Disease (ESRD) Therapy Introduction
11.4.4 Nipro Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022)
11.4.5 Nipro Recent Developments
11.5 B. Braun
11.5.1 B. Braun Company Details
11.5.2 B. Braun Business Overview
11.5.3 B. Braun End Stage Renal Disease (ESRD) Therapy Introduction
11.5.4 B. Braun Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022)
11.5.5 B. Braun Recent Developments
11.6 Asahi Kasei
11.6.1 Asahi Kasei Company Details
11.6.2 Asahi Kasei Business Overview
11.6.3 Asahi Kasei End Stage Renal Disease (ESRD) Therapy Introduction
11.6.4 Asahi Kasei Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022)
11.6.5 Asahi Kasei Recent Developments
11.7 Nikkiso
11.7.1 Nikkiso Company Details
11.7.2 Nikkiso Business Overview
11.7.3 Nikkiso End Stage Renal Disease (ESRD) Therapy Introduction
11.7.4 Nikkiso Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022)
11.7.5 Nikkiso Recent Developments
11.8 WEGO
11.8.1 WEGO Company Details
11.8.2 WEGO Business Overview
11.8.3 WEGO End Stage Renal Disease (ESRD) Therapy Introduction
11.8.4 WEGO Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022)
11.8.5 WEGO Recent Developments
11.9 Newsol
11.9.1 Newsol Company Details
11.9.2 Newsol Business Overview
11.9.3 Newsol End Stage Renal Disease (ESRD) Therapy Introduction
11.9.4 Newsol Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022)
11.9.5 Newsol Recent Developments
11.10 Mayo Clinic
11.10.1 Mayo Clinic Company Details
11.10.2 Mayo Clinic Business Overview
11.10.3 Mayo Clinic End Stage Renal Disease (ESRD) Therapy Introduction
11.10.4 Mayo Clinic Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022)
11.10.5 Mayo Clinic Recent Developments
11.11 Guangdong Biolight
11.11.1 Guangdong Biolight Company Details
11.11.2 Guangdong Biolight Business Overview
11.11.3 Guangdong Biolight End Stage Renal Disease (ESRD) Therapy Introduction
11.11.4 Guangdong Biolight Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022)
11.11.5 Guangdong Biolight Recent Developments
11.12 Medtronic
11.12.1 Medtronic Company Details
11.12.2 Medtronic Business Overview
11.12.3 Medtronic End Stage Renal Disease (ESRD) Therapy Introduction
11.12.4 Medtronic Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022)
11.12.5 Medtronic Recent Developments
11.13 Sanxin Medtec
11.13.1 Sanxin Medtec Company Details
11.13.2 Sanxin Medtec Business Overview
11.13.3 Sanxin Medtec End Stage Renal Disease (ESRD) Therapy Introduction
11.13.4 Sanxin Medtec Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022)
11.13.5 Sanxin Medtec Recent Developments
11.14 Jafron Biomedical
11.14.1 Jafron Biomedical Company Details
11.14.2 Jafron Biomedical Business Overview
11.14.3 Jafron Biomedical End Stage Renal Disease (ESRD) Therapy Introduction
11.14.4 Jafron Biomedical Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022)
11.14.5 Jafron Biomedical Recent Developments
11.15 SWS Hemodialysis Care
11.15.1 SWS Hemodialysis Care Company Details
11.15.2 SWS Hemodialysis Care Business Overview
11.15.3 SWS Hemodialysis Care End Stage Renal Disease (ESRD) Therapy Introduction
11.15.4 SWS Hemodialysis Care Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022)
11.15.5 SWS Hemodialysis Care Recent Developments
11.16 Tianyi Medical
11.16.1 Tianyi Medical Company Details
11.16.2 Tianyi Medical Business Overview
11.16.3 Tianyi Medical End Stage Renal Disease (ESRD) Therapy Introduction
11.16.4 Tianyi Medical Revenue in End Stage Renal Disease (ESRD) Therapy Business (2017-2022)
11.16.5 Tianyi Medical Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer